Cognition Cash Flow Coverage Ratios from 2010 to 2024

CGTX Stock  USD 0.43  0  0.93%   
Cognition Therapeutics Cash Flow Coverage Ratios yearly trend continues to be fairly stable with very little volatility. Cash Flow Coverage Ratios will likely drop to -24.23 in 2024. During the period from 2010 to 2024, Cognition Therapeutics Cash Flow Coverage Ratios regression line of annual values had significance of  0.0008 and arithmetic mean of (6.40). View All Fundamentals
 
Cash Flow Coverage Ratios  
First Reported
2010-12-31
Previous Quarter
(23.08)
Current Value
(24.23)
Quarterly Volatility
10.25400569
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 239.4 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Cash Flow Coverage Ratios Growth Pattern

Below is the plot of the Cash Flow Coverage Ratios of Cognition Therapeutics over the last few years. It is Cognition Therapeutics' Cash Flow Coverage Ratios historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flow Coverage Ratios10 Years Trend
Slightly volatile
   Cash Flow Coverage Ratios   
       Timeline  

Cognition Cash Flow Coverage Ratios Regression Statistics

Arithmetic Mean(6.40)
Coefficient Of Variation(160.24)
Mean Deviation8.75
Median(0.45)
Standard Deviation10.25
Sample Variance105.14
Range23.9629
R-Value(0.77)
Mean Square Error45.84
R-Squared0.60
Significance0.0008
Slope(1.77)
Total Sum of Squares1,472

Cognition Cash Flow Coverage Ratios History

2024 -24.23
2023 -23.08
2021 -21.96
2020 -0.27

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Cash Flow Coverage Ratios, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flow Coverage Ratios(23.08)(24.23)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.